A phase 2 study of fruquintinib in combination with S-1 for second-line treatment of esophageal squamous cell carcinoma after first-line immunotherapy failure.

被引：0
|
作者：
Li, Ningning
Ge, Yuping
Wang, Xiang
Qiu, Wei
Zhang, Zhiyang
Zhou, Na
Zhao, Lin
机构：
[1] Peking Union Med Coll Hosp, Beijing, Peoples R China
[2] Peking Union Med Coll Hosp, Dept Med Oncol, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-374; 283-424-6846-271-2644; 298-145-222-7468; 261-566-148; 130-540-543-4790; 613-135-244-3829-325; 261-492-2769; 4; 3; 2; 2461; 6;
D O I：
10.1200/JCO.2024.42.3_suppl.323
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：323 / 323
页数：1
相关论文
共 50 条
  • [1] Fruquintinib in combination with S-1 for ESCC patients after first-line immunotherapy failure: Update of dose-finding results
    Li, N.
    Ge, Y.
    Wang, X.
    Qiu, W.
    Zhang, Z.
    Zhou, N.
    Zhao, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S1478 - S1478
  • [2] Second-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma
    Song, Zhengbo
    Zhang, Yiping
    ONCOTARGETS AND THERAPY, 2014, 7 : 1875 - 1881
  • [3] First-line versus second-line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck
    Even, C.
    Torossian, N.
    Ibrahim, T.
    Martin, N.
    Badis, L. Mayache
    Ferrand, F. R.
    Iacob, M.
    Guigay, J.
    Le Tourneau, C.
    Daste, A.
    Saada-Bouzid, E.
    Saleh, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] Apatinib plus S-1 as second-line or later line treatment for advanced squamous cell lung carcinoma
    Shi, Q.
    Xia, L.
    Zhou, J.
    Wang, Z.
    Sheng, L.
    Wang, G.
    Wang, L.
    Cheng, X.
    Wang, F.
    Kong, F.
    Zhao, F.
    Li, X.
    Ye, B.
    Mei, L.
    Liu, Y.
    Pan, L.
    Xie, J.
    Cheng, G.
    Li, X.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Phase II study of S-1 as a first-line, S-1 plus cisplatin as a second-line, and weekly paclitaxel as a third-line therapy in patients with advanced gastric carcinoma
    Yamada, T.
    Rino, Y.
    Kanari, M.
    Saeki, H.
    Yukawa, N.
    Wada, N.
    Ooshima, T.
    Yamada, R.
    Haruhiko, C.
    Masuda, M.
    Imada, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Real-world outcomes in patients with first-line and second-line therapy for advanced esophageal squamous cell carcinoma
    Ahn, Daniel
    Sidel, Michelle
    Panattoni, Laura
    Sacks, Naomi
    Hernandez, Jennifer
    Villacorta, Reginald
    FUTURE ONCOLOGY, 2022, 18 (30) : 3419 - 3433
  • [7] Retrospective study of continued immunotherapy in patients with advanced esophageal squamous cell carcinoma after progression on first-line immunotherapy combination chemotherapy.
    Yu, Weiyong
    Wan, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Second-Line Treatment Outcomes After First-Line Sunitinib Therapy in Metastatic Renal Cell Carcinoma
    Chen, Chi-Chang
    Hess, Gregory P.
    Liu, Zhimei
    Gesme, Dean H.
    Agarwala, Sanjiv S.
    Garay, Carlos C.
    Hill, Jerrold W.
    Guo, Amy
    CLINICAL GENITOURINARY CANCER, 2012, 10 (04) : 256 - 261
  • [9] A Phase II Study of S-1 Monotherapy as a First-line Combination Therapy of S-1 Plus Cisplatin as a Second-line Therapy, and Weekly Paclitaxel Monotherapy as a Third-line Therapy in Patients with Advanced Gastric Carcinoma: A Second Report
    Rino, Yasushi
    Yukawa, Norio
    Murakami, Hitoshi
    Wada, Nobuyuki
    Yamada, Roppei
    Hayashi, Tsutomu
    Sato, Tsutomu
    Ohshima, Takashi
    Masuda, Munetaka
    Imada, Toshio
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2010, 4 : 1 - 10
  • [10] Regional Chemotherapy Is a Valuable Second-Line Approach in Metastatic Esophageal Cancer after Failure to First-Line Palliative Treatment
    Vashist, Yogesh
    Aigner, Kornelia
    Dam, Miriam
    Gailhofer, Sabine
    Aigner, Karl R.
    CURRENT ONCOLOGY, 2022, 29 (07) : 4868 - 4878
12345